ENROLLED
Page 1 of 4
CODING: Words in struck through type are deletions from existing law; words underscored
are additions.
Regular Session, 2013
HOUSE BILL NO. 15
BY REPRESENTATIVES MACK, BROADWATER, TI M BURNS, COX, CROMER,
HARRISON, HOWARD, IVEY, NANCY LANDRY, LORUSSO, MILLER,
MORENO, PEARSON, POPE, REYNOLDS, SCHEXNAYDER, ST. GERMAIN,
STOKES, AND WHITNEY
Prefiled pursuant to Article III, Section 2(A)(4)(b)(i) of the Constitution of Louisiana.
AN ACT1
To amend and reenact R.S. 40:964(Schedule I)(E)(9)(i) and (iii) and (F) and to enact R.S.2
40:961(26.1), relative to controlled dangerous substances; to provide with respect to3
certain chemical groups within the cathinone Schedule I stimulants; to add4
substances to the listing of synthetic cannabinoids in Schedule I; to provide for5
definitions; to provide for certain exceptions; and to provide for related matters.6
Be it enacted by the Legislature of Louisiana:7
Section 1. R.S. 40:964(Schedule I)(E)(9)(i) and (iii) and (F) are hereby amended and8
reenacted and R.S. 40:961(26.1) is hereby enacted to read as follows: 9
§961. Definitions10
As used in this Part, the following terms shall have the meaning ascribed to11
them in this Section unless the context clearly indicates otherwise:12
* * *13
(26.1) "Nitrogen-heterocyclic analog" means a nitrogen-heterocyclic analog14
of a synthetic cannabinoid which has a single carbon atom in a cyclic structure of a15
compound replaced by a nitrogen atom.16
* * *17
§964. Composition of schedules18
Schedules I, II, III, IV, and V shall, unless and until added to pursuant to R.S.19
40:962, consist of the following drugs or other substances, by whatever official20
name, common or usual name, chemical name, or brand name designated:21 ENROLLEDHB NO. 15
Page 2 of 4
CODING: Words in struck through type are deletions from existing law; words underscored
are additions.
SCHEDULE I1
* * *2
E. Stimulants. Unless specifically excepted, or contained within a3
pharmaceutical product approved by the United States Federal Food and Drug4
Administration, or unless listed in another schedule, any material, compound,5
mixture, or preparation which contains any quantity of the following substances6
having a stimulant effect on the central nervous system including its salts, isomers,7
esters, or ethers and salts of isomers, esters, or ethers whenever the existence of such8
salts, isomers, esters, or ethers and salts of isomers, esters, or ethers is possible9
within the specific chemical designation:10
* * *11
(9) 2-amino-1-phenyl-1-propanone (cathinone) or variation in any of the12
following ways:13
(i) By substitution in the phenyl ring to any extent with alkyl, hydroxyl14
alkoxy, alkylenedioxy, haloalkyl or halide substituents, whether or not further15
substituted in the phenyl ring by one or more other univalent substituents.16
(ii) By substitution at the 3-position with an alkyl substituent.17
(iii) By substitution at the 2-amino nitrogen atom with alkyl, dialkyl, or18
benzyl groups, or methoxybenzyl groups, or by inclusion of the 2-amino nitrogen19
atom in a cyclic structure.20
F. Synthetic cannabinoids. Unless specifically excepted, or contained within21
a pharmaceutical product approved by the United States Food and Drug22
Administration, or unless listed in another schedule, any material, compound,23
mixture, or preparation, which contains any quantity of a synthetic cannabinoid24
found to be in any of the following chemical groups, or any of those groups which25
contain any synthetic cannabinoid salts, isomers, or salts of isomers, or nitrogen-26
heterocyclic analogs, whenever the existence of such salts, isomers, or salts of27
isomers, or nitrogen-heterocyclic analogs is possible within the specific chemical28
designation, including all synthetic cannabinoid chemical analogues in such groups:29 ENROLLEDHB NO. 15
Page 3 of 4
CODING: Words in struck through type are deletions from existing law; words underscored
are additions.
(1) Naphthoylindoles : any compound containing a 3-(1-naphthoyl)indole1
structure, whether or not substituted in the indole ring to any extent or the naphthyl2
ring to any extent.3
(2) Naphthylmethylindoles : any compound containing a 1-H-indol-3-yl-(1-4
naphthyl)methane structure, whether or not substituted in the indole ring to any5
extent or the naphthyl ring to any extent.6
(3) Naphthoylpyrroles : any compound containing a 3-(1-naphthoyl)pyrrole7
structure, whether or not substituted in the pyrrole ring to any extent or the naphthyl8
ring to any extent.9
(4) Naphthylmeth ylindenes: any compound containing a 1-(1-10
naphthylmethyl)indene structure, whether or not substituted in the indene ring to any11
extent or the naphthyl ring to any extent.12
(5) Phenylacetylindoles : any compound containing a 3-phenylacetylindole13
structure, whether or not substituted in the indole ring to any extent or the phenyl14
ring to any extent.15
(6) Cyclohexylphenols : any compound containing a 2-(3-16
hydroxycyclohexyl)phenol structure, whether or not substituted in the cyclohexyl17
ring to any extent or the phenyl ring to any extent.18
(7) Dibenzopyrans whether or not substituted in the cyclohexyl ring to any19
extent or the phenyl ring to any extent.20
(8)(7) Benzoylindoles : any compound containing a 3-(benzoyl)indole21
structure, whether or not substituted in the indole ring to any extent or the phenyl22
ring to any extent.23
(9)(8) (1-pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone24
Tetrahydrodibenzopyrans whether or not substituted in the tricyclic ring system25
except where contained in cannabis or cannabis resin.26
(10)(9) (1-(5-fluoropenty l)indol-3-y l)27
-(2,2,3,3-tetramethylcyclopropyl)met hanone Hexahydrodibenzopyrans whether or28
not substituted in the tricyclic ring system except where contained in cannabis or29
cannabis resin.30 ENROLLEDHB NO. 15
Page 4 of 4
CODING: Words in struck through type are deletions from existing law; words underscored
are additions.
(10) Cyclopropanoylindoles: any compound containing a 3-1
(cyclopropanoyl)indole structure, whether or not substituted in the indole ring to any2
extent or the cyclopropyl ring to any extent.3
(11) Adamantoylindoles: any compound containing a 3-(1-4
adamantoyl)indole structure, whether or not further substituted in the indole ring to5
any extent or whether or not substituted in the adamantyl ring to any extent.6
(12) Naphthylamidoindoles: any compound containing a7
N-(naphthyl)-indole-3-carboxamide structure, whether or not further substituted in8
the indole ring to any extent or whether or not substituted in the naphthyl ring to any9
extent.10
(13) Quinolinylindolecarboxylates: any compound containing a11
quinolin-8-yl-1H-indole-3-carboxylate structure, whether or not substituted in the12
indole ring to any extent or the quinloline ring to any extent.13
(14) Adamantylamidoindoles: Any compound containing a14
N-(adamantyl)-indole-3-carboxamide structure, whether or not further substituted15
in the indole ring to any extent or whether or not substituted in the adamantyl ring16
to any extent.17
* * *18
SPEAKER OF THE HOUSE OF REPRESENTATI VES
PRESIDENT OF THE SENATE
GOVERNOR OF THE STATE OF LOUISIANA
APPROVED: